Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
K287859-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $61.90 | |
K287859-10mg | 10mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $103.90 | |
K287859-25mg | 25mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $234.90 | |
K287859-50mg | 50mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $416.90 | |
K287859-100mg | 100mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $757.90 |
Highly potent and selective MAGL inhibitor.
Synonyms | KML29|KML-29|1380424-42-9|1,1,1,3,3,3-hexafluoropropan-2-yl 4-[bis(1,3-benzodioxol-5-yl)-hydroxymethyl]piperidine-1-carboxylate|KML 29|1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(benzo[d][1,3]dioxol-5-yl)(hydroxy)methyl)piperidine-1-carboxylate|GTPL9482|CHEM |
---|---|
Specifications & Purity | Moligand™, ≥96% |
Biochemical and Physiological Mechanisms | Highly selective and potent monoacylglycerol lipase (MAGL) inhibitor. Exhibits potent inhibition of human, mouse and rat MAGL (IC50values are 5.9, 15 and 43 nM, respectively). Exhibits no detectable inhibition of FAAH (IC50> 50000 nM). Potently and select |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of Monoacylglycerol lipase |
Product Description | Product Describtion: KML29 is an extremely selective, orally active and irreversible inhibitor of MAGL with IC50 of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[bis(1,3-benzodioxol-5-yl)-hydroxymethyl]piperidine-1-carboxylate |
---|---|
INCHI | InChI=1S/C24H21F6NO7/c25-23(26,27)20(24(28,29)30)38-21(32)31-7-5-13(6-8-31)22(33,14-1-3-16-18(9-14)36-11-34-16)15-2-4-17-19(10-15)37-12-35-17/h1-4,9-10,13,20,33H,5-8,11-12H2 |
InChi Key | SXHQLPHDBLTFPM-UHFFFAOYSA-N |
Canonical SMILES | C1CN(CCC1C(C2=CC3=C(C=C2)OCO3)(C4=CC5=C(C=C4)OCO5)O)C(=O)OC(C(F)(F)F)C(F)(F)F |
Isomeric SMILES | C1CN(CCC1C(C2=CC3=C(C=C2)OCO3)(C4=CC5=C(C=C4)OCO5)O)C(=O)OC(C(F)(F)F)C(F)(F)F |
Alternate CAS | 1380424-42-9 |
PubChem CID | 71656212 |
MeSH Entry Terms | 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(benzo(d)(1,3)dioxol-5-yl)(hydroxy)methyl)piperidine-1-carboxylate;KML29 compound |
Molecular Weight | 549.42 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2213034 | Certificate of Analysis | Jun 01, 2022 | K287859 |
G2213035 | Certificate of Analysis | Jun 01, 2022 | K287859 |
G2213068 | Certificate of Analysis | Jun 01, 2022 | K287859 |
G2213070 | Certificate of Analysis | Jun 01, 2022 | K287859 |
G2213114 | Certificate of Analysis | Jun 01, 2022 | K287859 |
Solubility | Solvent:DMSO, Max Conc. mg/mL: 54.94, Max Conc. mM: 100 |
---|
1. Ignatowska-Jankowska BM, Ghosh S, Crowe MS, Kinsey SG, Niphakis MJ, Abdullah RA, Tao Q, O' Neal ST, Walentiny DM, Wiley JL et al.. (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects.. Br J Pharmacol, 171 (6): (1392-407). [PMID:23848221] |